Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07308886 · ClinicalTrials.gov registry record · Phase 2
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
A Phase 2 study of Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT07308886 is a Phase 2 study of Kaposi Sarcoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants, below the 98-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07308886, a Phase 2 study of Kaposi Sarcoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the United States. Having HIV can weaken the immune system and this can lead to KS. Weaker immune systems may be measured by low T cells (a type of immune cell). CYT107 is a human protein, made in a laboratory, that may help boost immunity, specifically by increasing T cells, in people with HIV-associated KS. Objective: To see if CYT107 can shrink KS tumors. Eligibility: People aged 18 years and older with HIV-associated KS. Design: Participants will be screened. They will have a physical exam with blood tests. Their skin lesions will be measured. They will have an x-ray of their lungs. Their ability to perform everyday tasks will be reviewed. A sample of lesion tissue (biopsy) may be collected from the skin. CYT107 is injected into the muscle of the arm, buttocks, or lower thigh once a week for up to 4 weeks. Participants will receive the shots at the clinic. Blood and other tests will be repeated at each visit. KS lesions will be measured and photographed on the 1st and 4th visits. Participants who improved after the first 4 weeks may have another 4-week treatment within a year. Follow-up visits will continue for 3 years.
Conditions Studied
Interventions
- DRUG CYT107
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2037-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07308886
The ClinicalTrials.gov registry entry for NCT07308886 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (44% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which CYT107 is the first listed.
NCT07308886 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07308886 about?
NCT07308886 is a clinical study titled "Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)". Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the United States. Having H...
What is the current status of trial NCT07308886?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2026-03-26. Estimated completion is 2037-01-31.
What conditions does trial NCT07308886 study?
This clinical trial studies the following conditions: Kaposi Sarcoma.
What interventions are being tested in trial NCT07308886?
The interventions under investigation include: CYT107 (DRUG).
Who is sponsoring clinical trial NCT07308886?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07308886 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
A Study of sEphB4-HSA in Kaposi Sarcoma
RECRUITING · Phase 2
-
Propranolol for the Treatment of Kaposi Sarcoma in Adults
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.